Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $138.09 in the prior trading day, Transmedics Group Inc (NASDAQ: TMDX) closed at $135.3, down -2.02%. In other words, the price has decreased by -$2.02 from its previous closing price. On the day, 0.65 million shares were traded. TMDX stock price reached its highest trading level at $138.95 during the session, while it also had its lowest trading level at $135.04.
Ratios:
Our goal is to gain a better understanding of TMDX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.32. For the most recent quarter (mrq), Quick Ratio is recorded 7.13 and its Current Ratio is at 7.69. In the meantime, Its Debt-to-Equity ratio is 1.46 whereas as Long-Term Debt/Eq ratio is at 1.44.
On October 13, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $145.
On September 16, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $155.Evercore ISI initiated its Outperform rating on September 16, 2025, with a $155 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 03 ’25 when Weill David sold 5,000 shares for $138.64 per share. The transaction valued at 693,200 led to the insider holds 12,134 shares of the business.
Hernandez Gerardo sold 920 shares of TMDX for $128,450 on Dec 04 ’25. The Chief Financial Officer now owns 15,064 shares after completing the transaction at $139.62 per share. On Dec 03 ’25, another insider, DAVID WEILL, who serves as the Director of the company, bought 5,000 shares for $138.64 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4623785984 and an Enterprise Value of 4676961280. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 54.65, and their Forward P/E ratio for the next fiscal year is 46.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.16 while its Price-to-Book (P/B) ratio in mrq is 13.01. Its current Enterprise Value per Revenue stands at 8.258 whereas that against EBITDA is 38.797.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.04, which has changed by 1.2154903 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $156.00, while it has fallen to a 52-week low of $58.54. The 50-Day Moving Average of the stock is 2.86%, while the 200-Day Moving Average is calculated to be 12.61%.
Shares Statistics:
The stock has traded on average 854.68K shares per day over the past 3-months and 829720 shares per day over the last 10 days, according to various share statistics. A total of 34.14M shares are outstanding, with a floating share count of 32.99M. Insiders hold about 3.47% of the company’s shares, while institutions hold 110.32% stake in the company. Shares short for TMDX as of 1767139200 were 7201077 with a Short Ratio of 8.43, compared to 1764288000 on 7716642. Therefore, it implies a Short% of Shares Outstanding of 7201077 and a Short% of Float of 36.14.
Earnings Estimates
The firm’s stock currently is rated by 9.0 analysts. The consensus estimate for the next quarter is $0.7, with high estimates of $0.82 and low estimates of $0.49. Analysts are recommending an EPS of between $2.82 and $2.38 for the fiscal current year, implying an average EPS of $2.58. EPS for the following year is $2.91, with 10.0 analysts recommending between $3.52 and $2.24.
Revenue Estimates
10 analysts predict $155.41M in revenue. The current quarter. It ranges from a high estimate of $157.9M to a low estimate of $152.1M. The current estimate, Transmedics Group Inc’s year-ago sales were $121.62MFor the next quarter, 10 analysts are estimating revenue of $171.1M. There is a high estimate of $181.5M for the next quarter, whereas the lowest estimate is $163.4M.
A total of 13 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $602.6M, while the lowest revenue estimate was $599M, resulting in an average revenue estimate of $600.57M. In the same quarter a year ago, actual revenue was $441.54MBased on 12 analysts’ estimates, the company’s revenue will be $725.09M in the next fiscal year. The high estimate is $753.9M and the low estimate is $686.8M.
